Understand the source comparison
The BDNF-Dependent vs BDNF-Independent Divide
P21 operates through an entirely different neurotrophic pathway. It is a synthetic derivative of activity-dependent neurotrophic factor (ADNF), a peptide endogenously released by astrocytes in response to vasoactive intestinal peptide (VIP) signalling. Unlike
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- P21 operates through an entirely different neurotrophic pathway. It is a synthetic derivative of activity-dependent neurotrophic factor (ADNF), a peptide endogenously released by astrocytes in response to vasoactive intestinal peptide (VIP) signalling. Unlike PE-22-28 or BDNF itself, P21 does not require receptor-mediated endocytosis; it crosses the blood-brain barrier through passive diffusion due to its amphipathic structure and activates intracellular STAT3 phosphorylation directly. This makes it particularly valuable for models where blood-brain barrier integrity is compromised. Traumatic brain injury, ischaemic stroke, or models involving transient receptor dysfunction.
- Cerebrolysin occupies a distinct category altogether. It is not a single peptide but a standardised mixture of low-molecular-weight neuropeptides derived from porcine brain tissue, including fragments with BDNF-like, nerve growth factor (NGF)-like, and ciliary neurotrophic factor (CNTF)-like activity. The multi-modal mechanism makes direct potency comparisons to single-peptide alternatives difficult, but clinical trial data from over 1,500 patients in post-stroke cognitive recovery studies provide a level of translational validation that PE-22-28, Dihexa, and P21 do not yet possess.